BRPI0716811B8 - anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases - Google Patents
anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástasesInfo
- Publication number
- BRPI0716811B8 BRPI0716811B8 BRPI0716811A BRPI0716811A BRPI0716811B8 BR PI0716811 B8 BRPI0716811 B8 BR PI0716811B8 BR PI0716811 A BRPI0716811 A BR PI0716811A BR PI0716811 A BRPI0716811 A BR PI0716811A BR PI0716811 B8 BRPI0716811 B8 BR PI0716811B8
- Authority
- BR
- Brazil
- Prior art keywords
- alpha receptor
- ovarian carcinoma
- metastases
- cocktail
- diagnosing
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 2
- 229940014144 folate Drugs 0.000 title abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title abstract 2
- 235000019152 folic acid Nutrition 0.000 title abstract 2
- 239000011724 folic acid Substances 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 244000005700 microbiome Species 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003432 anti-folate effect Effects 0.000 abstract 1
- 229940127074 antifolate Drugs 0.000 abstract 1
- 239000004052 folic acid antagonist Substances 0.000 abstract 1
- 238000011363 radioimmunotherapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019399.2 | 2006-09-15 | ||
| EP06019399A EP1900752A1 (en) | 2006-09-15 | 2006-09-15 | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| PCT/EP2007/007944 WO2008031577A1 (en) | 2006-09-15 | 2007-09-12 | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0716811A2 BRPI0716811A2 (pt) | 2013-11-05 |
| BRPI0716811B1 BRPI0716811B1 (pt) | 2020-11-24 |
| BRPI0716811B8 true BRPI0716811B8 (pt) | 2021-05-25 |
Family
ID=37737768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0716811A BRPI0716811B8 (pt) | 2006-09-15 | 2007-09-12 | anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8388972B2 (enExample) |
| EP (2) | EP1900752A1 (enExample) |
| JP (1) | JP5513114B2 (enExample) |
| KR (1) | KR101497045B1 (enExample) |
| AU (1) | AU2007296899B2 (enExample) |
| BR (1) | BRPI0716811B8 (enExample) |
| CA (1) | CA2662005C (enExample) |
| ES (1) | ES2644423T3 (enExample) |
| IL (1) | IL197300A (enExample) |
| MX (1) | MX2009002711A (enExample) |
| NZ (1) | NZ575093A (enExample) |
| RU (1) | RU2464277C2 (enExample) |
| WO (1) | WO2008031577A1 (enExample) |
| ZA (1) | ZA200901328B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| AU2006241099B2 (en) | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| SG10201501342UA (en) * | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| EP2614084A4 (en) | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE |
| SG189957A1 (en) * | 2010-11-05 | 2013-06-28 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| US20140010756A1 (en) | 2011-03-18 | 2014-01-09 | Kagoshima University | Composition for treatment and diagnosis of pancreatic cancer |
| SI2694106T1 (en) * | 2011-04-01 | 2018-04-30 | Immunogen, Inc. | Methods for increasing the effectiveness of treatment with FOLR1 receptor cancer |
| SI2731972T1 (en) | 2011-07-15 | 2018-04-30 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| WO2013026839A1 (en) * | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| US9200073B2 (en) * | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CA3222465A1 (en) | 2013-08-30 | 2015-03-05 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| PT3055332T (pt) * | 2013-10-08 | 2019-12-09 | Immunogen Inc | Regimes de dosagem de imunoconjugados anti-folr1 |
| KR101646577B1 (ko) * | 2014-08-14 | 2016-08-09 | 원광대학교산학협력단 | 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물 |
| CN107074955B (zh) | 2014-11-20 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子 |
| LT3789402T (lt) | 2014-11-20 | 2022-09-26 | F. Hoffmann-La Roche Ag | Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus |
| RS60615B1 (sr) | 2014-11-20 | 2020-08-31 | Hoffmann La Roche | Zajednički laki lanci i postupci upotrebe |
| CN116440279A (zh) | 2015-09-17 | 2023-07-18 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| EP3496757A4 (en) | 2016-08-12 | 2020-04-15 | L.E.A.F Holdings Group LLC | POLYGLUTAMATE ANTIFOLATES AND USES THEREOF. |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2019094648A1 (en) | 2017-11-08 | 2019-05-16 | L.E.A.F. Holdings Group Llc | Platinum complexes and uses thereof |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN115925952A (zh) | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR20220004687A (ko) | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 이중파라토프 fr-알파 항체 및 면역접합체 |
| CA3149914A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CN111393528B (zh) * | 2020-01-19 | 2023-01-31 | 中国药科大学 | 一种靶向叶酸受体α的单链抗体及其应用 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
| CN119757601A (zh) * | 2025-01-06 | 2025-04-04 | 哈尔滨脉图精准技术有限公司 | 一种用于卵巢癌诊断的代谢标志物组合及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| KR101461408B1 (ko) * | 2005-10-06 | 2014-11-13 | 어드밴스드 엑셀러레이터 어플리케이션즈 에스.에이. | 신규 선택 시스템 |
-
2006
- 2006-09-15 EP EP06019399A patent/EP1900752A1/en not_active Withdrawn
-
2007
- 2007-09-12 CA CA2662005A patent/CA2662005C/en active Active
- 2007-09-12 ES ES07802280.3T patent/ES2644423T3/es active Active
- 2007-09-12 AU AU2007296899A patent/AU2007296899B2/en active Active
- 2007-09-12 RU RU2009114161/10A patent/RU2464277C2/ru active
- 2007-09-12 JP JP2009527737A patent/JP5513114B2/ja active Active
- 2007-09-12 ZA ZA200901328A patent/ZA200901328B/xx unknown
- 2007-09-12 MX MX2009002711A patent/MX2009002711A/es not_active Application Discontinuation
- 2007-09-12 WO PCT/EP2007/007944 patent/WO2008031577A1/en not_active Ceased
- 2007-09-12 US US12/441,207 patent/US8388972B2/en active Active
- 2007-09-12 NZ NZ575093A patent/NZ575093A/en unknown
- 2007-09-12 KR KR1020097004948A patent/KR101497045B1/ko active Active
- 2007-09-12 BR BRPI0716811A patent/BRPI0716811B8/pt active IP Right Grant
- 2007-09-12 EP EP07802280.3A patent/EP2061813B1/en active Active
-
2009
- 2009-02-26 IL IL197300A patent/IL197300A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008031577A1 (en) | 2008-03-20 |
| CA2662005A1 (en) | 2008-03-20 |
| IL197300A0 (en) | 2011-08-01 |
| BRPI0716811B1 (pt) | 2020-11-24 |
| ES2644423T3 (es) | 2017-11-28 |
| JP2010503386A (ja) | 2010-02-04 |
| US8388972B2 (en) | 2013-03-05 |
| EP1900752A1 (en) | 2008-03-19 |
| IL197300A (en) | 2016-02-29 |
| NZ575093A (en) | 2012-04-27 |
| KR20090059114A (ko) | 2009-06-10 |
| CA2662005C (en) | 2018-01-02 |
| KR101497045B1 (ko) | 2015-02-27 |
| RU2009114161A (ru) | 2010-10-20 |
| BRPI0716811A2 (pt) | 2013-11-05 |
| AU2007296899B2 (en) | 2012-09-13 |
| AU2007296899A1 (en) | 2008-03-20 |
| MX2009002711A (es) | 2009-06-18 |
| JP5513114B2 (ja) | 2014-06-04 |
| EP2061813B1 (en) | 2017-07-19 |
| EP2061813A1 (en) | 2009-05-27 |
| RU2464277C2 (ru) | 2012-10-20 |
| US20100055034A1 (en) | 2010-03-04 |
| WO2008031577A8 (en) | 2009-07-02 |
| ZA200901328B (en) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0716811B8 (pt) | anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases | |
| ES2560532T3 (es) | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6) | |
| BRPI0812913A8 (pt) | Anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos | |
| BRPI0923359B8 (pt) | molécula de anticorpo anti-igf, método para a produção da mesma, molécula de dna, vetor de expressão, e composição farmacêutica e método in vitro para inibir a ligação do igf-1 e do igf-2 ao receptor de igf-1 e ao receptor de insulina ir-a | |
| BR112013021236A8 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
| PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| EA200870234A1 (ru) | Моноклональное анти-мет антитело, его фрагменты и векторы для лечения опухолей и соответствующие продукты | |
| BRPI0819909B8 (pt) | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica | |
| AR086693A1 (es) | PROTEINAS HUMANAS DE UNION AL ANTIGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE b-KLOTHO Y UN RECEPTOR PARA FGF | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
| EA200702064A1 (ru) | Новое анти-plgf антитело | |
| PE20140625A1 (es) | ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| BR112015021595A2 (pt) | anticorpos anti-tgf-beta engenheirados e fragmentos de ligação do antígeno | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
| MX384227B (es) | Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis. | |
| BRPI0816049A2 (pt) | anticorpos an-a5ß1, molecula de ácido nucléico isolada, vetor de expressão anticorpos, método de produção de um anticorpo, composições, método para a detecção da proteina a5ß1, uso de anticorpo, método para inibir a angiogênese e/ou permeabilidade ou extravasamento vascular, métodos para tratar um câncer, para tratar um doença ocular e para tratar uma doença autoimune | |
| PE20140633A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
| PE20081625A1 (es) | Proteinas de union al antigeno del receptor a de la il-17 | |
| BRPI0715660B8 (pt) | anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal | |
| CO6251291A2 (es) | Anticuerpos humanizados contra el globulomero ab (20-42) y sus usos | |
| EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ISTITUTO NAZIONALE PER STUDIO E LA CURA DEI TUMORI |
|
| B25A | Requested transfer of rights approved |
Owner name: ISTITUTO NAZIONALE PER STUDIO E LA CURA DEI TUMORI |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |